Eight Advisory supported Ampersand Capital Partners in the context of its acquisition of Julius Clinical Research

The investment and partnership with Ampersand will enable the Julius Clinical Research to expand its scientific and therapeutic expertise as well as build its geographic footprint in Europe and North America to accelerate growth of its CRO services.

Julius Clinical Research, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of neurology, renal, cardiometabolic and infectious diseases, Julius Clinical has grown to approximately 200 employees and has supported over 130 clinical trials, enrolling more than 200,000 participants in around 40 countries.

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, Massachusetts, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors.

Eight Advisory financial due diligence team consisted of: Hans Bogaardt (Partner), Joris Peers (Director), Fábio Gonçalves Viegas (Manager), Luuk Hintzen (Senior) and Thomas Fleury (Analyst).

The tax due diligence team consisted of: Christian Van Craeyvelt (Partner) and Bram de Roo (Manager).